Suppr超能文献

[ALK激活模式变化与晚期肺癌靶向治疗的研究进展]

[Research Progress of ALK Activation Pattern Changes and Targeted Therapy 
in Advanced Lung Cancer].

作者信息

Wei Aojiao, Jiang Bo, Huang Yurong, Liu Mengyun, Yan Jing, Zhao Yuanyuan, He Wenjie

机构信息

Kunming Medical University, Kunming 650500, China.

Department of Geriatric Oncology, The Third Affiliated Hospital of 
Kunming Medical University, Kunming 650118, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2024 Dec 20;27(12):940-946. doi: 10.3779/j.issn.1009-3419.2024.102.45.

Abstract

Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.
.

摘要

肺癌是中国乃至全球最常见的癌症,也是癌症死亡的主要原因。间变性淋巴瘤激酶(ALK)基因改变的患者有机会接受分子靶向治疗。间变性淋巴瘤激酶抑制剂,如ALK-酪氨酸激酶抑制剂(ALK-TKIs)可显著延长患者生存期。ALK基因变异类型包括点突变、扩增、融合/重排,其中ALK融合比其他类型更常见。然而,不同类型的基因改变在分子靶向治疗中的效果有所不同。因此,本文介绍了ALK基因不同变体的相关内容,重点阐述了靶向治疗的研究进展,并提出了未来的发展方向。

相似文献

5
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验